Change in Board of Managing Directors to ensure continuity and focus on the future
• Prof Andreas Barner to move to Shareholders’ Committee
• Hubertus von Baumbach to succeed as Chairman of the Board of Managing Directors as of 1 July 2016
• Dr Michel Pairet to become member of the Board of Managing Directors with responsibility for Corporate Board Division Research and Nonclinical Development as of 1 January 2016
Ingelheim, 6 November 2015 – After 24 years’ service to Boehringer Ingelheim, Professor Andreas Barner will retire as Chairman of the Board of Managing Directors on 30 June 2016 and will move to the Shareholders' Committee of Boehringer Ingelheim. After completing his doctorate in medicine and mathematics, Professor Barner joined Boehringer Ingelheim in 1992 as Head of the Medical Division. He became a member of the Board of Managing Directors in 1999, and has been Chairman since 2009. Christian Boehringer, Chairman of the Shareholders’ Committee, thanked Andreas Barner for his many years of wide-ranging service, during which time he realigned the company’s research, development, and medical activities. His successful work enabled Boehringer Ingelheim to introduce many innovative drugs and thereby offer doctors highly effective treatment alternatives for the benefit of their patients. This was particularly instrumental in further consolidating and expanding Boehringer Ingelheim’s independence as a family-owned company.
Christian Boehringer: “All of us at Boehringer Ingelheim, the shareholder family, the advisory board, as well as the colleagues on the Board of Managing Directors and, last but not least, the employees would like to thank Professor Barner for his successful work. His leadership has made a lasting impression on the corporate values and culture of our company. Furthermore, we are very pleased that the company will continue to benefit from Professor Barner’s experience and advice in the future in his new role as a member of the Shareholders’ Committee.”
He will be succeeded by Hubertus von Baumbach, whom the shareholders have appointed as the new Chairman of the Board of Managing Directors. Christian Boehringer said that this decision provided a successor who would ensure continuity whilst also looking to the future: “Hubertus von Baumbach knows the corporation and its various divisions and his time on the Board of Managing Directors has prepared him well for the company’s future challenges. Along with colleagues on the Board of Managing Directors, he will continue the drive for change at Boehringer Ingelheim in order to secure the company’s independence in the long term.“
Hubertus von Baumbach completed a banking apprenticeship and the first and second German state legal examinations, before going on to receive an MBA from MIT in Cambridge, USA. He has been a member of the Board of Managing Directors since 2009 and is Head of the Corporate Board Division Finance. Following periods at Roche in the USA and at BI in Canada, he performed various functions in the finance division at Boehringer Ingelheim in Germany.
From 1 January 2016, Dr Michel Pairet will become a member of the Board of Managing Directors with responsibility for the Corporate Business Division Research and Nonclinical Development. Dr Michel Pairet studied veterinary medicine in Toulouse, France and came to Boehringer Ingelheim in 1992, where he led the Pharmacology Unit at the research facility in Biberach. Dr Pairet has taken on ever greater responsibility in the area of research with management roles including respiratory research, the Corporate Venture Fund and, since 2013, worldwide pharmaceutical research and nonclinical development.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales